Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

Journal of Virology

Volumn 84, Issue 6, 2010, Pages 2955-2962

  Ofek, Gilad ^a   McKee, Krisha ^a   Yang, Yongping ^a   Yang, Zhi Yong ^a   Skinner, Jeff ^a   Guenaga, F Javier ^a,b   Wyatt, Richard ^a,b   Zwick, Michael B ^b   Nabel, Gary J ^a   Mascola, John R ^a   Kwong, Peter D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2F5 ANTIBODY; EPITOPE; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; OCTANOL; TRYPTOPHAN; UNCLASSIFIED DRUG; WATER;

ARTICLE; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ENERGY TRANSFER; HEAVY CHAIN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; LIPID BILAYER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS ISOLATION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; COMPLEMENTARITY DETERMINING REGIONS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; HYDROPHOBICITY; IMMUNOLOGIC FACTORS; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77649132440     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02257-09     Document Type: Article

References (47)

1. Alam, S. M., M. McAdams, D. Boren, M. Rak, R. M. Scearce, F. Gao, Z. T. Camacho, D. Gewirth, G. Kelsoe, P. Chen, and B. F. Haynes. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178: 4424-4435.
2. Alam, S. M., M. Morelli, S. M. Dennison, H. X. Liao, R. Zhang, S. M. Xia, S. Rits-Volloch, L. Sun, S. C. Harrison, B. F. Haynes, and B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 106:20234-20239.
3. Alving, C. R. 2008. 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 22:649-651.
4. Barbato, G., E. Bianchi, P. Ingallinella, W. H. Hurni, M. D. Miller, G. Ciliberto, R. Cortese, R. Bazzo, J. W. Shiver, and A. Pessi. 2003. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330:1101-1115.
5. Barouch, D. H., Z. Y. Yang, W. P. Kong, B. Korioth-Schmitz, S. M. Sumida, D. M. Truitt, M. G. Kishko, J. C. Arthur, A. Miura, J. R. Mascola, N. L. Letvin, and G. J. Nabel. 2005. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79: 8828-8834. 6. Binley, J. M., E. A. Lybarger, E. T. Crooks, M. S. Seaman, E. Gray, K. L. Davis, J. M. Decker, D. Wycuff, L. Harris, N. Hawkins, B. Wood, C. Nathe, D. Richman, G. D. Tomaras, F. Bibollet-Ruche, J. E. Robinson, L. Morris, G. M. Shaw, D. C. Montefiori, and J. R. Mascola. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
6. Biron, Z., S. Khare, S. R. Quadt, Y. Hayek, F. Naider, and J. Anglister. 2005. The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20. Biochemistry 44:13602-13611.
7. Biron, Z., S. Khare, A. O. Samson, Y. Hayek, F. Naider, and J. Anglister. 2002. A monomeric 310-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry 41:12687-12696.
8. Bryson, S., J. P. Julien, R. C. Hynes, and E. F. Pai. 2009. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-HIV-1 antibody 2F5: vaccine design implications. J. Virol. 83:11862-11875.
9. de la Arada, I., J. P. Julien, B. G. de la Torre, N. Huarte, D. Andreu, E. F. Pai, J. L. Arrondo, and J. L. Nieva. 2009. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5. J. Phys Chem. B 113:13626-13637.
10. Grundner, C., T. Mirzabekov, J. Sodroski, and R. Wyatt. 2002. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76:3511-3521.
11. Haynes, B. F., J. Fleming, E. W. St. Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, T. L. Ortel, H. X. Liao, and S. M. Alam. 2005. Immunology: cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
12. Huang, C. C., F. Stricher, L. Martin, J. M. Decker, S. Majeed, P. Barthe, W. A. Hendrickson, J. Robinson, C. Roumestand, J. Sodroski, R. Wyatt, G. M. Shaw, C. Vita, and P. D. Kwong. 2005. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120: crystal structures, molecular mimicry, and neutralization breadth. Structure 13:755-768.
13. Julien, J. P., S. Bryson, J. L. Nieva, and E. F. Pai. 2008. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 384:377-392.
14. Kutner, M. H. 2005. Applied linear statistical models, 5th ed. McGraw-Hill Irwin, Boston, MA.
15. 2-bungarotoxin: potassium channel binding by Kunitz modules and targeted phospholipase action. Structure 3:1109-1119.
16. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, and D. C. Montefiori. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
17. Li, Y., S. A. Migueles, B. Welcher, K. Svehla, A. Phogat, M. K. Louder, X. Wu, G. M. Shaw, M. Connors, R. T. Wyatt, and J. R. Mascola. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
18. Liu, J., Y. Deng, A. K. Dey, J. P. Moore, and M. Lu. 2009. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry 48:2915-2923.
19. Mackenzie, D., A. Arendt, P. Hargrave, J. H. Mcdowell, and R. S. Molday. 1984. Localization of binding-sites for carboxyl terminal specific anti-rhodopsin monoclonal-antibodies using synthetic peptides. Biochemistry 23: 6544-6549.
20. Mascola, J. R., G. Stiegler, T. C. Vancott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
21. Matyas, G. R., Z. Beck, N. Karasavvas, and C. R. Alving. 2009. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta 1788:660-665.
22. Munoz-Barroso, I., K. Salzwedel, E. Hunter, and R. Blumenthal. 1999. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J. Virol. 73:6089-6092.
23. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
24. Ofek, G., M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, and P. D. Kwong. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737.
25. Persson, S., J. A. Killian, and G. Lindblom. 1998. Molecular ordering of interfacially localized tryptophan analogs in ester- and ether-lipid bilayers studied by 2H-NMR. Biophys. J. 75:1365-1371.
26. Purtscher, M., A. Trkola, G. Gruber, A. Buchacher, P. Predl, F. Steindl, C. Tauer, R. Berger, N. Barrett, A. Jungbauer, and H. Katinger. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 10:1651-1658.
27. Salzwedel, K., J. T. West, and E. Hunter. 1999. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73:2469-2480.
28. Sanchez-Martinez, S., M. Lorizate, H. Katinger, R. Kunert, G. Basanez, and J. L. Nieva. 2006. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 580: 2395-2399.
29. Sanchez-Martinez, S., M. Lorizate, H. Katinger, R. Kunert, and J. L. Nieva. 2006. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res. Hum. Retrovir. 22:998-1006.
30. Scherer, E. M., M. B. Zwick, L. Teyton, and D. R. Burton. 2007. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-2139.
31. Schibli, D. J., R. C. Montelaro, and H. J. Vogel. 2001. The membraneproximal tryptophan-rich region of the HIV glycoprotein, gp41 forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 40:9570-9578.
32. Scott, D. L., Z. Otwinowski, M. H. Gelb, and P. B. Sigler. 1990. Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue. Science 250:1563-1566.
33. Scott, D. L., S. P. White, Z. Otwinowski, W. Yuan, M. H. Gelb, and P. B. Sigler. 1990. Interfacial catalysis: the mechanism of phospholipase A2. Science 250:1541-1546.
34. Snider, C., S. Jayasinghe, K. Hristova, and S. H. White. 2009. MPEx: a tool for exploring membrane proteins. Protein Sci. 18:2624-2628.
35. Suarez, T., W. R. Gallaher, A. Agirre, F. M. Goni, and J. L. Nieva. 2000. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J. Virol. 74:8038-8047.
36. Sun, Z. Y. J., K. J. Oh, M. Kim, J. Yu, V. Brusic, L. Song, Z. Qiao, J. H. Wang, G. Wagner, and E. L. Reinherz. 2008. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63.
37. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R. Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto, and H. F. Gunthard. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622.
38. Vcelar, B., G. Stiegler, H. M. Wolf, W. Muntean, B. Leschnik, S. Mehandru, M. Markowitz, C. Armbruster, R. Kunert, M. M. Eibl, and H. Katinger. 2007. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21:2161-2170.
39. White, S. H., and W. C. Wimley. 1999. Membrane protein folding and stability: physical principles. Annu. Rev. Biophys. Biomol. Struct. 28:319-365.
40. White, S. P., D. L. Scott, Z. Otwinowski, M. H. Gelb, and P. B. Sigler. 1990. Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. Science 250:1560-1563.
41. Wimley, W. C., T. P. Creamer, and S. H. White. 1996. Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides. Biochemistry 35:5109-5124.
42. Wimley, W. C., and S. H. White. 1996. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat. Struct. Biol. 3:842-848.
43. Wu, X. L., T. Q. Zhou, S. O'Dell, R. T. Wyatt, P. D. Kwong, and J. R. Mascola. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody b12 that effectively targets the site of CD4 attachment. J. Virol. 83:10892-10907.
44. Yuste, E., H. B. Sanford, J. Carmody, J. Bixby, S. Little, M. B. Zwick, T. Greenough, D. R. Burton, D. D. Richman, R. C. Desrosiers, and W. E. Johnson. 2006. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J. Virol. 80:3030-3041.
45. Zhou, T., L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, J. Arthos, D. R. Burton, D. S. Dimitrov, J. Sodroski, R. Wyatt, G. J. Nabel, and P. D. Kwong. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
46. Zwick, M. B., H. K. Komori, R. L. Stanfield, S. Church, M. Wang, P. W. H. I. Parren, R. Kunert, H. Katinger, I. A. Wilson, and D. R. Burton. 2004. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78:3155-3161.
47. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. Ollmann Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. H. I. Parren. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.